MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ophthotech Corp Company Profile (NASDAQ:OPHT)

Consensus Ratings for Ophthotech Corp (NASDAQ:OPHT) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $88.00 (69.26% upside)

Analysts' Ratings History for Ophthotech Corp (NASDAQ:OPHT)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$60.00 -> $84.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2016BarclaysInitiated CoverageOverweight$85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$128.00 -> $91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016SunTrustInitiated CoverageBuy$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015OppenheimerReiterated RatingOutperform$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Goldman SachsDowngradeNeutral -> Sell$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Stifel NicolausReiterated RatingBuy$74.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/3/2015Leerink SwannReiterated RatingOutperform$69.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2014GabelliInitiated CoverageBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Ophthotech Corp (NASDAQ:OPHT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q116($1.33)($1.03)$7.22 million$15.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q415($1.35)($1.02)$7.59 million$4.78 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.98)($1.14)$11.31 million$3.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($1.02)($1.08)$2.77 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.75)$0.22$3.68 million$41.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015Q414($0.57)($1.06)$12.36 million$1.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.62)$0.31$8.02 million$39.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.56)($1.57)$4.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q1($0.67)($0.64)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014($0.50)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q313($1.00)($10.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ophthotech Corp (NASDAQ:OPHT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.50)($1.35)($1.43)
Q2 20163($1.24)($0.66)($0.89)
Q3 20163($1.69)($0.74)($1.30)
Q4 20163($1.83)($0.34)($1.22)
(Data provided by Zacks Investment Research)
Dividend History for Ophthotech Corp (NASDAQ:OPHT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ophthotech Corp (NASDAQ:OPHT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Axel BolteDirectorBuy3,500$56.97$199,395.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Glenn SblendorioCFOSell671$57.20$38,381.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016David R GuyerCEOSell30,060$52.71$1,584,462.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Samir Chandrakant PatelPresidentSell20,000$53.32$1,066,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016A/S NovoMajor ShareholderSell1,300,000$49.00$63,700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016David R GuyerCEOSell22,060$46.18$1,018,730.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016Samir Chandrakant PatelPresidentSell20,000$46.79$935,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016David R GuyerCEOSell22,060$44.11$973,066.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/29/2016Samir Chandrakant PatelPresidentSell20,000$41.85$837,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016David R GuyerCEOSell22,060$45.48$1,003,288.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Samir Chandrakant PatelPresidentSell20,000$45.13$902,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Samir Chandrakant PatelPresidentSell20,000$53.59$1,071,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2016David R. GuyerCEOSell18,598$53.63$997,410.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Nicholas GalakatosDirectorSell3,000$65.72$197,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Barbara A. WoodSVPSell1,000$76.37$76,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015David R. GuyerCEOSell18,582$78.82$1,464,633.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Glenn SblendorioDirectorSell2,000$80.00$160,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Samir Chandrakant PatelPresidentSell1,184$77.50$91,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2015Samir Chandrakant PatelPresidentSell26,036$77.09$2,007,115.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Nicholas GalakatosDirectorSell3,000$64.44$193,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Barbara A. WoodSVPSell2,000$63.24$126,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015David R. GuyerCEOSell18,582$62.49$1,161,189.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Samir Chandrakant PatelPresidentSell27,215$60.27$1,640,248.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Nicholas GalakatosDirectorSell1,500$60.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2015Samir Chandrakant PatelPresidentSell20,687$53.55$1,107,788.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Samir Chandrakant PatelPresidentSell27,215$43.27$1,177,593.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Barbara A. WoodSVPSell2,000$45.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015David R. GuyerCEOSell18,582$37.69$700,355.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Samir Chandrakant PatelPresidentSell27,215$46.34$1,261,143.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015David R. GuyerCEOSell18,582$44.88$833,960.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Samir Chandrakant PatelPresidentSell27,215$48.75$1,326,731.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Samir Chandrakant PatelPresidentSell27,215$67.87$1,847,082.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Glenn SblendorioDirectorSell3,000$67.33$201,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Barbara A WoodSVPSell2,000$51.94$103,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015David R GuyerCEOSell18,582$51.05$948,611.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Samir Chandrakant PatelPresidentSell12,000$49.78$597,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2015David R GuyerCEOSell18,582$48.62$903,456.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2015David R GuyerCEOSell18,582$48.45$900,297.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Samir Chandrakant PatelPresidentSell12,000$50.47$605,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Axel BolteDirectorBuy500$48.27$24,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015David R GuyerCEOSell18,582$48.26$896,767.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Barbara A WoodSVPSell2,000$53.26$106,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David R GuyerCEOSell18,582$53.22$988,934.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015David R GuyerCEOSell15,034$45.34$681,641.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014A/S NovoMajor ShareholderSell995,000$40.20$39,999,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014David R GuyerCEOSell15,034$39.71$597,000.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014David R GuyerCEOSell2,807$38.52$108,125.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Samir Chandrakant PatelPresidentSell1,965$38.04$74,748.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014David R GuyerCEOSell12,227$37.30$456,067.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Samir Chandrakant PatelPresidentSell17,676$37.28$658,961.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014David R GuyerCEOSell1,107$38.58$42,708.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Bruce PeacockCFOSell6,191$37.78$233,895.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014David R GuyerCEOSell13,136$37.85$497,197.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Samir Chandrakant PatelPresidentSell18,986$37.80$717,670.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Bruce PeacockCFOSell7,739$41.07$317,840.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014David R GuyerCEOSell15,034$41.08$617,596.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Samir Chandrakant PatelPresidentSell18,986$41.08$779,944.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Nicholas GalakatosDirectorSell144,976$44.17$6,403,589.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell211,680$45.42$9,614,505.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Svlsf Iv, LlcMajor ShareholderSell1,966,935$42.54$83,673,414.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Bruce PeacockCFOSell13,931$40.12$558,911.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Svlsf Iv, LlcMajor ShareholderSell1,865,619$40.65$75,837,412.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014David R GuyerCEOSell25,417$39.92$1,014,646.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Samir Chandrakant PatelPresidentSell27,873$39.91$1,112,411.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Svlsf Iv, LlcMajor ShareholderSell931,869$40.99$38,197,310.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2014Svlsf Iv, LlcMajor ShareholderSell980,127$40.19$39,391,304.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Svlsf Iv, LlcMajor ShareholderSell330,450$38.10$12,590,145.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Hbm Healthcare Investments (Camajor shareholderSell500,000$29.75$14,875,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Bruce PeacockCFOSell4,643$32.43$150,572.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014David GuyerCEOSell10,665$33.71$359,517.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Samir Chandrakant PatelPresidentSell14,319$32.45$464,651.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Bruce PeacockCFOSell6,137$34.77$213,383.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014David GuyerCEOSell12,027$34.53$415,292.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Samir Chandrakant PatelPresidentSell16,876$34.54$582,897.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Svlsf Iv, Llcmajor shareholderSell2,111,364$29.61$62,517,488.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013A/S NovoInsiderBuy455,000$22.00$10,010,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013Hbm Healthcare Investments (CaMajor ShareholderBuy228,000$22.00$5,016,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ophthotech Corp (NASDAQ:OPHT)
DateHeadline
06/23/16 06:11 PMOphthotech completes patient recruitment for third phase 3 trial of Fovista
06/23/16 08:21 AMAdd Up The Pieces: JKJ Could Be Worth $152
06/20/16 05:29 PMBRIEF-Ophthotech says achieved $30 mln enrollment milestone from Novartis Pharma
06/20/16 07:16 AMCompany Shares of Ophthotech Corporation Drops by -6.28% - Trade Calls
06/20/16 06:49 AMOphthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration - [at noodls] - June 20, 2016 - $30 Million Milestone Triggered by Reaching Final Enrollment Goal in the Third Phase 3 Trial in the Fovista Program - NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today ...
06/20/16 06:31 AM7:31 am Ophthotech completes patient recruitment in Phase 3 trial of Fovista anti-PDGF therapy in combination with Eylea or Avastin in wet age-related macular degeneration; triggers $30 million milestone from Novartis ( -
06/18/16 04:56 PMAnalyst Activity: Ophthotech Corp (NASDAQ:OPHT) - iStreetWire
06/17/16 05:28 PMMore Fovista Risk For Regeneron Than Investors Realize: Canaccord
06/15/16 05:36 PMOphthotech: Start Preparing For The Blockbuster - Fovista - Seeking Alpha
06/15/16 10:13 AMOphthotech: Start Preparing For The Blockbuster - Fovista
06/14/16 10:30 AMIs Ophthotech The Next Regeneron?
06/10/16 08:36 AMWhy Ophthotech Corp. Shares Soared 14.9% in May - Motley Fool
06/09/16 03:43 PMWhy Ophthotech Corp. Shares Soared 14.9% in May - Investors are growing optimistic about upcoming phase 3 trial results for the company's lead drug candidate.
06/09/16 08:38 AMJP Morgan Upgrades Ophthotech Corp to Overweight with Price Target $84.00 - Trade Calls
06/08/16 03:07 PMOPHTHOTECH CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off -
06/08/16 08:39 AMA Director at Ophthotech Corp (NASDAQ: OPHT) is Buying Shares - Analyst Ratings
06/05/16 08:22 AMSblendorio Glenn, EVP, COO & CFO, Treasurer of Ophthotech Corporation (NASDAQ:OPHT) sells 671 shares
06/04/16 01:54 PM3 Biotechs Expecting Market-Moving Trial Results Soon - Achillion Pharmaceuticals, Ophthotech Corp., and Kite Pharmaceuticals shares could move wildly because of upcoming trial data.
06/03/16 06:07 PMWill You Buy These Stocks? - Ophthotech Corporation (NASDAQ:OPHT), FelCor Lodging Trust Incorporated (NYSE:FCH) - Beacon Chronicle
06/03/16 06:07 PMStock that Got Upgrade: Ophthotech Corp (NASDAQ:OPHT) - The Point Review
06/02/16 06:02 PMUPDATE: JPMorgan Upgrades Ophthotech Corp (OPHT) to Overweight - StreetInsider.com - UPDATE: JPMorgan Upgrades Ophthotech Corp (OPHT) to OverweightStreetInsider.comJPMorgan upgraded Ophthotech Corp (NASDAQ: OPHT) from Neutral to Overweight with a price target of $84.00 (from $60.00). Analyst Anupam Rama sees a high probability of success for its phase 3 Fovista / Lucentis combination trials. Positive data could ...Ophthotech Corp (NASDAQ:OPHT)'s Company Shares Increased 20.05% After Low VolatilityFranklin IndependentOphthotech Corp (OPHT) is Upgraded by JP Morgan to OverweightMarket DigestOphthotech Corp (OPHT) Upgraded to Overweight by JPMorgan Chase & Co.Let Me Know About ThisThe Post -Risers & Fallers -Share Trading Newsall 11 news articles »
06/01/16 08:35 AMForm SC 13D/A Ophthotech Corp. Filed by: Novo A/S - StreetInsider.com - Form SC 13D/A Ophthotech Corp. Filed by: Novo A/SStreetInsider.comThis Amendment No. 4 relates to the shares of Common Stock of Ophthotech Corporation, a Delaware corporation (the “Issuer”). The Issuer's principal executive office is located at One Penn Plaza, 35th Floor, New York, New York 10119.Do You Know More Than Novo AS about Ophthotech Corp?The Postall 2 news articles »
06/01/16 08:35 AMOphthotech Corp (OPHT) Jumps 5.01% on May 31 - Equities.com - Ophthotech Corp (OPHT) Jumps 5.01% on May 31Equities.comOphthotech Corp (OPHT) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 5.01% to $53.70, representing a gain of $2.56 per share. Some 640,042 shares traded hands on 5,728 trades, compared with an average ...and more »
05/31/16 09:31 AMOphthotech Corporation to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - Business Wire (press release) - Ophthotech Corporation to Present at the Goldman Sachs 37th Annual Global Healthcare ConferenceBusiness Wire (press release)NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37th Annual Global Healthcare Conference in ...and more »
05/29/16 06:58 PMOphthotech Corporation (NASDAQ:OPHT) Short Interest Increased By 4.05% - HNN - Ophthotech Corporation (NASDAQ:OPHT) Short Interest Increased By 4.05%HNNThe stock of Ophthotech Corporation (NASDAQ:OPHT) registered an increase of 4.05% in short interest. OPHT's total short interest was 2.79M shares in May as published by FINRA. Its up 4.05% from 2.68M shares, reported previously. With 412,000 shares ...Hold Calls Count For Ophthotech Corporation (NASDAQ:OPHT) At 1Equities Focusall 3 news articles »
05/28/16 07:00 PMPopeyes Louisiana Kitchen Inc 21.3% Potential Upside Now Implied by Maxim Group - The current average broker rating for Ophthotech Corporation (NASDAQ:OPHT) is 1.28. The company's stock had a trading volume of 225,801 shares. The 1 year high for the stock price is 63 Dollars while the 52 week low for the stock is 49.11 USD. Putting all ...
05/28/16 01:13 AMLargest Insiders' Trades of the Week - The price is 21.25% below its 52-week high and 115% above its 52-week low. On May 24, Novo A/S, 10% owner of Ophthotech Corp. (OPHT), sold 1,300,000 shares in the company at the price of $49 per share. Since then, the price of the stock has risen by 3.9% ...
05/26/16 07:37 PMForm 4 Ophthotech Corp. For: May 24 Filed by: Novo A/S - StreetInsider.com - Form 4 Ophthotech Corp. For: May 24 Filed by: Novo A/SStreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. FORM 4, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. STATEMENT OF CHANGES IN BENEFICIAL ...and more »
05/20/16 07:02 PMOphthotech Corporation (NASDAQ:OPHT) Short Interest Decreased By 2.72% - Wall Street Hints and News - Ophthotech Corporation (NASDAQ:OPHT) Short Interest Decreased By 2.72%Wall Street Hints and NewsThe stock of Ophthotech Corporation (NASDAQ:OPHT) registered a decrease of 2.72% in short interest. OPHT's total short interest was 2.68M shares in May as published by FINRA. Its down 2.72% from 2.75 million shares, reported previously. With 434,400 ...and more »
05/18/16 09:44 PMETF’s with exposure to Ophthotech Corp. : May 19, 2016 -
05/18/16 07:05 PMOphthotech : What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech - Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and ...
05/18/16 12:04 PMOPHTHOTECH CORP. Financials -
05/17/16 06:48 PMRevenue Update on Ophthotech Corp(NASDAQ:OPHT) - Trade Calls - Revenue Update on Ophthotech Corp(NASDAQ:OPHT)Trade CallsOphthotech Corp(NASDAQ:OPHT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 4, 2016. Company reported revenue of $15.72M. Analysts estimated a revenue of $7.22M. Earnings per share ...Analyst Recommendations On Ophthotech Corporation (NASDAQ:OPHT)News Tribuneall 3 news articles »
05/17/16 06:48 PMOphthotech Corp (OPHT) Jumps 5.76% on May 16 - Equities.com - Ophthotech Corp (OPHT) Jumps 5.76% on May 16Equities.comOphthotech Corp (OPHT) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 5.76% to $46.48, representing a gain of $2.53 per share. Some 395,868 shares traded hands on 3,958 trades, compared with an average ...and more »
05/17/16 11:18 AMAnalysts Forecast 39% Gains Ahead For BIB - Three of BIB's underlying holdings with notable upside to their analyst target prices are ProNAi Therapeutics Inc (Symbol: DNAI), Ophthotech Corp (Symbol: OPHT), and Applied Genetic Technologies Corp (Symbol: AGTC). Although DNAI has traded at a recent ...
05/17/16 07:17 AMOphthotech Corp. breached its 50 day moving average in a Bullish Manner : OPHT-US : May 17, 2016 -
05/13/16 07:28 PMTwo Stocks within Traders Observation: Ophthotech Corporation (NASDAQ:OPHT) , Sagent Pharmaceuticals, Inc ... - Street Updates - Two Stocks within Traders Observation: Ophthotech Corporation (NASDAQ:OPHT) , Sagent Pharmaceuticals, Inc ...Street UpdatesOn 5/12/2016, Ophthotech Corporation (NASDAQ:OPHT) ended trading session lower at $44.29 with -0.67%. The company traded a volume of 322.88 thousand shares as comparison to average volume of 538.97 thousand shares. During the 52 –week ...and more »
05/10/16 12:24 AMOphthotech Corp (OPHT) Jumps 7.97% on May 09 - Equities.com - Ophthotech Corp (OPHT) Jumps 7.97% on May 09Equities.comOphthotech Corp (OPHT) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 7.97% to $46.04, representing a gain of $3.4 per share. Some 410,897 shares traded hands on 4,739 trades, compared with an average ...and more »
05/09/16 06:02 AMOPHTHOTECH CORP. Files SEC form 8-K, Change in Directors or Principal Officers -
05/05/16 08:35 PMOphthotech Corp (OPHT) Drops 5.85% on May 04 - Equities.com - Ophthotech Corp (OPHT) Drops 5.85% on May 04Equities.comOphthotech Corp (OPHT) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 5.85% to $41.84, a loss of $-2.6 per share. Starting at an opening price of $45.58 a share, the stock traded between $41.74 and $46.44 over the ...and more »
05/05/16 04:43 PMETF’s with exposure to Ophthotech Corp. : May 5, 2016 -
05/05/16 11:34 AMOphthotech Corp. :OPHT-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/04/16 07:29 PMOphthotech Corp Earnings Call (Q1 2016) - Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in ...
05/04/16 07:29 PMOphthotech Corporation: Ophthotech Reports First Quarter 2016 Financial and Operating Results - NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Company's business and product development programs. 'During the first quarter, we ...
05/04/16 07:29 PMOphthotech's (OPHT) CEO David Guyer on Q1 2016 Results - Earnings Call Transcript - Good day and welcome to the Ophthotech Corporation First Quarter 2016 Earnings Results Conference Call. Today’s conference is being recorded. At this time, it is my pleasure to turn the conference over to Kathy Galante. Please go ahead. Good morning and ...
05/04/16 07:29 PMOphthotech has jam-packed year ahead - Ophthotech Corporation (NASDAQ:OPHT) promised shareholders 2016 would be a particularly busy one for the eye disease specialist. “We look forward to providing initial, top-line data from our two pivotal Phase 3 trials of Fovista in combination with ...
05/04/16 07:29 PMOphthotech Corporation (NASDAQ:OPHT) Is Trading Down – Insiders Are Selling - Here is the rundown on market activity for Ophthotech Corporation. Yesterday President Samir Chandrakant Patel disclosed the sale of 20,000 shares of (OPHT). The shares were purchased at an average price of $47.25. Patel now owns $10,026,072 of the stock ...
05/04/16 06:41 AMOPHTHOTECH CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/04/16 06:40 AMOphthotech Reports First Quarter 2016 Financial and Operating Results - [at noodls] - May 4, 2016 - Conference Call and Webcast Today, May 4, at 8:00 a.m. ET - NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended ...
05/04/16 06:38 AMOphthotech reports 1Q loss -
About Ophthotech Corp

Ophthotech Corp logoOphthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OPHT
  • CUSIP:
Key Metrics:
  • Previous Close: $51.99
  • 50 Day Moving Average: $51.59
  • 200 Day Moving Average: $53.14
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.84B
  • Current Quarter EPS Consensus Estimate: $-4.86 EPS
Additional Links:
Ophthotech Corp (NASDAQ:OPHT) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha